Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.07
(4.24%)
EUR 0.07
(4.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.34 Million EUR | -4.0% |
| 2022 | -19.56 Million EUR | -229.49% |
| 2021 | -5.93 Million EUR | -645.18% |
| 2020 | 1.08 Million EUR | 103.23% |
| 2019 | -33.72 Million EUR | -258.85% |
| 2018 | -9.39 Million EUR | 84.09% |
| 2017 | -59.07 Million EUR | -160.56% |
| 2016 | -22.67 Million EUR | -16.81% |
| 2015 | -19.4 Million EUR | -152.11% |
| 2014 | -7.69 Million EUR | 49.75% |
| 2013 | -15.32 Million EUR | -32.67% |
| 2012 | -11.54 Million EUR | 21.02% |
| 2011 | -14.62 Million EUR | -620.49% |
| 2010 | 2.8 Million EUR | 118.26% |
| 2009 | -15.38 Million EUR | 28.0% |
| 2008 | -21.36 Million EUR | -17.08% |
| 2007 | -18.24 Million EUR | -38.61% |
| 2006 | -13.16 Million EUR | -71.25% |
| 2005 | -7.68 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.47 Million EUR | -25.95% |
| 2024 Q2 | -5.47 Million EUR | 0.0% |
| 2023 Q2 | -11.64 Million EUR | -100.0% |
| 2023 Q3 | -4.35 Million EUR | 62.64% |
| 2023 Q4 | -4.35 Million EUR | 0.0% |
| 2023 FY | -20.34 Million EUR | -4.0% |
| 2023 Q1 | -5.82 Million EUR | 28.04% |
| 2022 FY | -19.56 Million EUR | -229.49% |
| 2022 Q2 | -11.47 Million EUR | -100.0% |
| 2022 Q3 | -4.04 Million EUR | 64.73% |
| 2022 Q4 | -8.09 Million EUR | -100.0% |
| 2022 Q1 | -5.73 Million EUR | -391.47% |
| 2021 Q2 | -4.77 Million EUR | -100.0% |
| 2021 Q4 | -1.16 Million EUR | -100.0% |
| 2021 FY | -5.93 Million EUR | -645.18% |
| 2021 Q1 | -2.38 Million EUR | 39.67% |
| 2021 Q3 | -583.5 Thousand EUR | 87.77% |
| 2020 FY | 1.08 Million EUR | 103.23% |
| 2020 Q3 | -1.97 Million EUR | -139.2% |
| 2020 Q4 | -3.95 Million EUR | -100.0% |
| 2020 Q2 | 5.04 Million EUR | 100.0% |
| 2020 Q1 | 2.52 Million EUR | 110.0% |
| 2019 Q3 | -12.6 Million EUR | -48.17% |
| 2019 Q4 | -25.21 Million EUR | -100.0% |
| 2019 Q2 | -8.51 Million EUR | -100.0% |
| 2019 FY | -33.72 Million EUR | -258.85% |
| 2019 Q1 | -4.25 Million EUR | -1411.55% |
| 2018 Q1 | -4.41 Million EUR | 81.38% |
| 2018 FY | -9.39 Million EUR | 84.09% |
| 2018 Q4 | -281.5 Thousand EUR | 0.0% |
| 2018 Q3 | -281.5 Thousand EUR | 93.63% |
| 2018 Q2 | -4.41 Million EUR | 0.0% |
| 2017 Q4 | -23.72 Million EUR | 0.0% |
| 2017 FY | -59.07 Million EUR | -160.56% |
| 2017 Q1 | -5.81 Million EUR | -1.6% |
| 2017 Q2 | -5.81 Million EUR | 0.0% |
| 2017 Q3 | -23.72 Million EUR | -308.05% |
| 2016 Q3 | -5.72 Million EUR | -1.93% |
| 2016 FY | -22.67 Million EUR | -16.81% |
| 2016 Q1 | -5.61 Million EUR | -39.26% |
| 2016 Q2 | -5.61 Million EUR | 0.0% |
| 2016 Q4 | -5.72 Million EUR | 0.0% |
| 2015 Q1 | -5.67 Million EUR | -316.03% |
| 2015 Q2 | -5.67 Million EUR | 0.0% |
| 2015 FY | -19.4 Million EUR | -152.11% |
| 2015 Q4 | -4.03 Million EUR | 0.0% |
| 2015 Q3 | -4.03 Million EUR | 28.95% |
| 2014 Q1 | -6.47 Million EUR | -65.27% |
| 2014 FY | -7.69 Million EUR | 49.75% |
| 2014 Q3 | 2.62 Million EUR | 140.56% |
| 2014 Q2 | -6.47 Million EUR | 0.0% |
| 2014 Q4 | 2.62 Million EUR | 0.0% |
| 2013 FY | -15.32 Million EUR | -32.67% |
| 2013 Q2 | -3.74 Million EUR | 0.0% |
| 2013 Q1 | -3.74 Million EUR | 0.0% |
| 2013 Q3 | -3.91 Million EUR | -4.66% |
| 2013 Q4 | -3.91 Million EUR | 0.0% |
| 2012 FY | -11.54 Million EUR | 21.02% |
| 2011 FY | -14.62 Million EUR | -620.49% |
| 2010 FY | 2.8 Million EUR | 118.26% |
| 2009 FY | -15.38 Million EUR | 28.0% |
| 2008 FY | -21.36 Million EUR | -17.08% |
| 2007 FY | -18.24 Million EUR | -38.61% |
| 2006 FY | -13.16 Million EUR | -71.25% |
| 2005 FY | -7.68 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -478.283% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 86.23% |
| Adocia SA | -21.16 Million EUR | 3.865% |
| Aelis Farma SA | -5.07 Million EUR | -300.63% |
| Biophytis S.A. | -17.02 Million EUR | -19.488% |
| Advicenne S.A. | -7.03 Million EUR | -189.347% |
| genOway Société anonyme | 1.56 Million EUR | 1397.801% |
| IntegraGen SA | -171.39 Thousand EUR | -11769.381% |
| Medesis Pharma S.A. | -3.95 Million EUR | -413.803% |
| Neovacs S.A. | -8.74 Million EUR | -132.677% |
| NFL Biosciences SA | -3.74 Million EUR | -443.162% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 25796.927% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -541.575% |
| Sensorion SA | -22.06 Million EUR | 7.793% |
| Theranexus Société Anonyme | -6.82 Million EUR | -197.952% |
| TME Pharma N.V. | -6.73 Million EUR | -202.019% |
| Valbiotis SA | -7.36 Million EUR | -176.113% |
| TheraVet SA | -1.57 Million EUR | -1195.213% |
| DBV Technologies S.A. | -67.26 Million EUR | 69.757% |
| Genfit S.A. | -28.89 Million EUR | 29.591% |
| GeNeuro SA | -14.75 Million EUR | -37.86% |
| Innate Pharma S.A. | -7.57 Million EUR | -168.745% |
| Inventiva S.A. | -110.42 Million EUR | 81.577% |
| MaaT Pharma SA | -19.71 Million EUR | -3.18% |
| MedinCell S.A. | -25.03 Million EUR | 18.748% |
| Nanobiotix S.A. | -39.7 Million EUR | 48.756% |
| OSE Immunotherapeutics SA | -23 Million EUR | 11.559% |
| Poxel S.A. | -35.09 Million EUR | 42.023% |
| GenSight Biologics S.A. | -26.22 Million EUR | 22.41% |
| Transgene SA | -22.32 Million EUR | 8.886% |
| Valneva SE | -101.42 Million EUR | 79.943% |